AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7317246 — intervention group
Group type: COMPARATOR
Intervention: Oral atropine 30 microgram kg‐1 90 min before operation
Number of subjects: 0
Study 30442329 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cognitive behavioral therapy (ICART)
Number of subjects: 55
Study 30442329 — intervention group
Group type: COMPARATOR
Intervention: MET-CBT
Number of subjects: 55
Study 29120255 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone + Bromfenac
Number of subjects: 144
Study 29120255 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone + Nepafenac
Number of subjects: 144
Study 29120255 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone alone (Control group)
Number of subjects: 144
Study 29120255 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Dexamethasone + Bromfenac, Dexamethasone + Nepafenac, Dexamethasone alone)
Number of subjects: 144
Study 29120255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac group
Number of subjects: 144
Study 27513344 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Pidobenzone 4% combined with fractional CO2 laser or cryotherapy
Number of subjects: 0
Study 27513344 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 0
Study 24123094 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose C (10 mg mane and 5 mg tarde)
Number of subjects: 10
Study 24123094 — intervention group
Group type: COMPARATOR
Intervention: Dose A (20 mg mane and 10 mg tarde)
Number of subjects: 10
Study 24123094 — intervention group
Group type: COMPARATOR
Intervention: Dose B (10 mg mane and 10 mg tarde)
Number of subjects: 10
Study 21972847 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (daily immersion for 20 minutes after dinner)
Number of subjects: 60
Study 21972847 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% chlorhexidine (single immersion for 5 minutes at the end of the experimental period)
Number of subjects: 60
Study 21972847 — intervention group
Group type: COMPARATOR
Intervention: Control (daily overnight soaking in water)
Number of subjects: 60
Study 20200041 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib, 400 mg orally once daily for 1 year
Number of subjects: 713
Study 20200041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 713
Study 18567762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified cheddar cheese (DC)
Number of subjects: 80
Study 18567762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified low‐fat cheese (DLF)
Number of subjects: 80
Study 18567762 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid vitamin D supplement with food (DS+)
Number of subjects: 80
Study 18567762 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid vitamin D supplement without food (DS‐)
Number of subjects: 80
Study 18567762 — intervention group
Group type: COMPARATOR
Intervention: Placebo cheddar cheese
Number of subjects: 80
Study 18567762 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement
Number of subjects: 80
Study 16084849 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg daily) with Indinavir (800 mg) and Ritonavir (100 mg)
Number of subjects: 18
Study 16084849 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg daily) with Indinavir (800 mg) and Ritonavir (100 mg)
Number of subjects: 18
Study 12514444 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (observational study)
Number of subjects: 144
Study 11253442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nutritional intervention
Number of subjects: 0
Study 11253442 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11253442 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition session attendance
Number of subjects: 0
Study 11253442 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in psychosocial factors
Number of subjects: 0
Study 8958015 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbo fast low angle shot MRI during drug‐induced sleep
Number of subjects: 15
Study 8958015 — intervention group
Group type: COMPARATOR
Intervention: Visual inspection while awake
Number of subjects: 15
Study 1415200 — intervention group
Group type: EXPERIMENTAL
Intervention: Enisoprost (EP) 100 micrograms orally four times daily for 2 weeks
Number of subjects: 40
Study 1415200 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 40
Study 3905211 — intervention group
Group type: EXPERIMENTAL
Intervention: High P/S ratio diet (1.0)
Number of subjects: 54
Study 3905211 — intervention group
Group type: COMPARATOR
Intervention: Low P/S ratio diet (0.3)
Number of subjects: 54
Study 30963721 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention for 6 months, mean of 6.5 sessions delivered face to face and via telephone.
Number of subjects: 39
Study 30963721 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care) for 6 months.
Number of subjects: 39
Study 30963721 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention.
Number of subjects: 39
Study 30963721 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care).
Number of subjects: 39
Study 29420200 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Number of subjects: 305
Study 29420200 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 1,000 mg
Number of subjects: 305
Study 29420200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 26746456 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 100
Study 26746456 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (diet)
Number of subjects: 100
Study 26746456 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of exercise and diet
Number of subjects: 100
Study 26746456 — intervention group
Group type: COMPARATOR
Intervention: Control group (attention control)
Number of subjects: 100
Study 24823465 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (COM) with MET 1000 mg twice a day and roflumilast 500 μg every day
Number of subjects: 36
Study 24823465 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET) 1000 mg twice a day
Number of subjects: 36
Study 24823465 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (COM)
Number of subjects: 36
Study 24823465 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET)
Number of subjects: 36
Study 24823465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment interventions
Number of subjects: 36
Study 22702724 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (T)
Number of subjects: 641
Study 22702724 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 641
Study 20144231 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2_2 score
Number of subjects: 342
Study 20144231 — intervention group
Group type: EXPERIMENTAL
Intervention: PGR_5 score
Number of subjects: 342
Study 20144231 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO_10 score
Number of subjects: 342
Study 20144231 — intervention group
Group type: EXPERIMENTAL
Intervention: RISK_25 score
Number of subjects: 342
Study 20144231 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO_10 and PGR_5 scores
Number of subjects: 342
Study 18394099 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal respiratory support (nasal continuous positive airway pressure or nasal intermittent mandatory ventilation)
Number of subjects: 54
Study 18394099 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing without nasal respiratory support
Number of subjects: 54
Study 16473215 — intervention group
Group type: COMPARATOR
Intervention: On-axis incisions (OAI)
Number of subjects: 71
Study 16473215 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal relaxing incisions (LRI)
Number of subjects: 71
Study 12722398 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin with paclitaxel for platinum-sensitive patients
Number of subjects: 28
Study 12722398 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, topotecan, or liposomal doxorubicin for platinum-resistant cases
Number of subjects: 28
Study 12722398 — intervention group
Group type: EXPERIMENTAL
Intervention: New agents introduced into therapy
Number of subjects: 28
Study 9502647 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete AVJ ablation with permanent pacing
Number of subjects: 60
Study 9502647 — intervention group
Group type: COMPARATOR
Intervention: AVJ modification
Number of subjects: 60
Study 8116037 — intervention group
Group type: EXPERIMENTAL
Intervention: PTX 800 mg
Number of subjects: 0
Study 8116037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2506913 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (Nalcrom) 200 mg orally, four times daily, starting 3 days before and continuing up to 3 days after food ingestion challenge.
Number of subjects: 38
Study 2506913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 1069551 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraminidase-treated allogeneic myeloblasts
Number of subjects: 17
Study 1069551 — intervention group
Group type: COMPARATOR
Intervention: Sustaining chemotherapy alone
Number of subjects: 17
Study 30021394 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical compounds (NCs) containing red yeast rice and coenzyme Q10 added to diet for 2 months
Number of subjects: 104
Study 30021394 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 104
Study 27095389 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus ketamine
Number of subjects: 0
Study 27095389 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 23871707 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable, accelerometer-based navigation device
Number of subjects: 100
Study 23871707 — intervention group
Group type: COMPARATOR
Intervention: Extramedullary (EM) alignment guides
Number of subjects: 100
Study 23023384 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone treatment
Number of subjects: 80
Study 20816299 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial mask and bite-block appliance
Number of subjects: 22
Study 20816299 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 untreated Class III subjects)
Number of subjects: 22
Study 18417969 — intervention group
Group type: EXPERIMENTAL
Intervention: X3 (X2 plus interpersonal phone contact)
Number of subjects: 444
Study 18417969 — intervention group
Group type: COMPARATOR
Intervention: X1 (standard direct‐mailed procedures)
Number of subjects: 444
Study 18417969 — intervention group
Group type: COMPARATOR
Intervention: X2 (X1 plus culturally tailored materials)
Number of subjects: 444
Study 16235674 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 (prospective randomized controlled trials)
Number of subjects: 786
Study 16235674 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 (other prospective studies)
Number of subjects: 786
Study 16235674 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 3 (retrospective case‐controlled studies)
Number of subjects: 786
Study 16235674 — intervention group
Group type: COMPARATOR
Intervention: Type 4 (case reports)
Number of subjects: 786
Study 16235674 — intervention group
Group type: EXPERIMENTAL
Intervention: Median number of patients
Number of subjects: 786
Study 16235674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean number of authors per study
Number of subjects: 786
Study 16235674 — intervention group
Group type: COMPARATOR
Intervention: Mean number of authors per study in JNS
Number of subjects: 786
Study 11806652 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 0
Study 11806652 — intervention group
Group type: COMPARATOR
Intervention: IRM
Number of subjects: 0
Study 11806652 — intervention group
Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 0
Study 11806652 — intervention group
Group type: COMPARATOR
Intervention: Super‐EBA
Number of subjects: 0
Study 10098764 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary-care-centred follow-up
Number of subjects: 0
Study 10098764 — intervention group
Group type: COMPARATOR
Intervention: Specialist-centred follow-up
Number of subjects: 0
Study 7541089 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeloxazine hydrochloride (INDX) with allylestrenol (ALE)
Number of subjects: 36
Study 7541089 — intervention group
Group type: COMPARATOR
Intervention: Allylestrenol (ALE) only
Number of subjects: 36
Study 1978469 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 62
Study 1978469 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 62
Study 1978469 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (Chlorpromazine and Remoxipride)
Number of subjects: 62
Study 1978469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 351804 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (specific dosage and duration not mentioned)
Number of subjects: 0
Study 351804 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 7109747 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-Belief-Model postcard
Number of subjects: 283
Study 7109747 — intervention group
Group type: COMPARATOR
Intervention: Neutral postcard
Number of subjects: 283
Study 7109747 — intervention group
Group type: COMPARATOR
Intervention: No postcard
Number of subjects: 283
Study 7109747 — intervention group
Group type: COMPARATOR
Intervention: Personal postcard signed by physician
Number of subjects: 283
Study 31008736 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 30 mg
Number of subjects: 50
Study 31008736 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg
Number of subjects: 50
Study 30203755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic atomized inhalation of antibiotics with targeted nursing
Number of subjects: 200
Study 26655434 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program emphasizing aerobic and resistance training for 4 months
Number of subjects: 0
Study 26655434 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 25138990 — intervention group
Group type: EXPERIMENTAL
Intervention: PlasmaKinetic urethrotomy
Number of subjects: 136
Study 25138990 — intervention group
Group type: COMPARATOR
Intervention: Cold knife urethrotomy
Number of subjects: 136
Study 22545928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-based test of deception measuring ocular-motor responses (pupil responses and reading behaviors) during a computerized questionnaire.
Number of subjects: 0
Study 22545928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-based test of deception with increased incentives to pass the test and simple syntax statements.
Number of subjects: 0
Study 22545928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular-motor measures used in a discrimination function.
Number of subjects: 0
Study 18547784 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene
Number of subjects: 119
Study 18547784 — intervention group
Group type: COMPARATOR
Intervention: Conventional polyethylene
Number of subjects: 119
Study 17804680 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals rich in oleic acid
Number of subjects: 11
Study 17804680 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals rich in EPA and DHA
Number of subjects: 11
Study 17804680 — intervention group
Group type: COMPARATOR
Intervention: Meals rich in palmitic acid
Number of subjects: 11
Study 17804680 — intervention group
Group type: COMPARATOR
Intervention: Meals rich in linoleic acid
Number of subjects: 11
Study 15459584 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic agents (ASSENT-2 trial participants)
Number of subjects: 3741
Study 15459584 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolytic agents (non-A2 patients at trial hospitals)
Number of subjects: 3741
Study 15459584 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolytic agents (non-A2-Hosp patients)
Number of subjects: 3741
Study 12492612 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol (25 mg kg‐1 6 hourly for 72 h) + Fosphenytoin (18 mg kg‐1)
Number of subjects: 28
Study 12492612 — intervention group
Group type: COMPARATOR
Intervention: Fosphenytoin (18 mg kg‐1) + Cefotaxime (25 mg kg‐1 8 hourly for 72 h)
Number of subjects: 28
Study 9828778 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 0.2%
Number of subjects: 71
Study 9828778 — intervention group
Group type: COMPARATOR
Intervention: Natamycin 2.5%
Number of subjects: 71
Study 7926381 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM with microangiopathy
Number of subjects: 55
Study 7926381 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM without microangiopathy
Number of subjects: 55
Study 7926381 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 55
Study 2790218 — intervention group
Group type: EXPERIMENTAL
Intervention: Total abstinence from alcohol without disulfiram
Number of subjects: 0
Study 2790218 — intervention group
Group type: EXPERIMENTAL
Intervention: Detoxification while taking disulfiram
Number of subjects: 0
Study 776348 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (Prothromplex)
Number of subjects: 0
Study 776348 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vitamin K1 (2-5 mg)
Number of subjects: 0
Study 31074236 — intervention group
Group type: COMPARATOR
Intervention: CCRT with weekly cisplatin followed by observation (arm A)
Number of subjects: 259
Study 31074236 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT with paclitaxel plus carboplatin every 4 weeks for 3 cycles (arm B)
Number of subjects: 259
Study 28221668 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) - moderate PA including walking, resistance and balance training
Number of subjects: 1635
Study 28221668 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE) - consisting of topics relevant to older adults
Number of subjects: 1635
Study 25846209 — intervention group
Group type: EXPERIMENTAL
Intervention: rBet v 1 tablets (12.5-50 μg) administered once daily for 5 months
Number of subjects: 483
Study 23780805 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 26
Study 21827215 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's Wort (SJW) 325 mg three times daily for 14 days
Number of subjects: 15
Study 21827215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 21827215 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's Wort (SJW)
Number of subjects: 15
Study 19019686 — intervention group
Group type: EXPERIMENTAL
Intervention: FTa angle assessment
Number of subjects: 68
Study 19019686 — intervention group
Group type: EXPERIMENTAL
Intervention: FTb angle measurement
Number of subjects: 68
Study 19019686 — intervention group
Group type: EXPERIMENTAL
Intervention: Short knee images
Number of subjects: 68
Study 17289297 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral economic measure of alcohol demand (demand curves)
Number of subjects: 51
Study 17289297 — intervention group
Group type: EXPERIMENTAL
Intervention: O(max) (maximum alcohol expenditure)
Number of subjects: 51
Study 17289297 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakpoint (sensitivity of consumption to increasing price)
Number of subjects: 51
Study 14736787 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide
Number of subjects: 30
Study 14736787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11776596 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐PCR for CEA mRNA detection
Number of subjects: 53
Study 11776596 — intervention group
Group type: EXPERIMENTAL
Intervention: RIA for CEA protein detection
Number of subjects: 53
Study 11776596 — intervention group
Group type: COMPARATOR
Intervention: Cytologic examination of peritoneal washings
Number of subjects: 53
Study 11776596 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA mRNA expression
Number of subjects: 53
Study 15251534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose pure follicle-stimulating hormone (FSH)
Number of subjects: 32
Study 15251534 — intervention group
Group type: COMPARATOR
Intervention: Human menopausal gonadotropins (hMG)
Number of subjects: 32
Study 1622160 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg loracarbef
Number of subjects: 6
Study 1622160 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg loracarbef
Number of subjects: 6
Study 1622160 — intervention group
Group type: COMPARATOR
Intervention: Killing curves against 12 strains of bacteria
Number of subjects: 6
Study 6151506 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol
Number of subjects: 369
Study 6151506 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol
Number of subjects: 369
Study 6151506 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 369
Study 30690509 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-gp41 antibody levels
Number of subjects: 683
Study 30690509 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of viral suppression
Number of subjects: 683
Study 30690509 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 DNA levels
Number of subjects: 683
Study 29601897 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin and warmth
Number of subjects: 85
Study 29601897 — intervention group
Group type: COMPARATOR
Intervention: Active control (warmth)
Number of subjects: 85
Study 27548448 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ocriplasmin 125 µg injection
Number of subjects: 0
Study 26510099 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated literacy- and math-focused preschool curriculum with explicit socioemotional lesson component
Number of subjects: 760
Study 26510099 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated literacy- and math-focused preschool curriculum without explicit socioemotional lesson component
Number of subjects: 760
Study 26510099 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual condition
Number of subjects: 760
Study 23535809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice slushy ingestion (ICE)
Number of subjects: 10